Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CCEL 
CryoCell International Inc (CCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.98% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.87M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta 0.73 | 52 Weeks Range 4.09 - 8.62 | Updated Date 08/29/2025 |
52 Weeks Range 4.09 - 8.62 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 13.68% | Basic EPS (TTM) -0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.54% | Operating Margin (TTM) 18.83% |
Management Effectiveness
Return on Assets (TTM) 3.76% | Return on Equity (TTM) 129.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 49607411 | Price to Sales(TTM) 1.18 |
Enterprise Value 49607411 | Price to Sales(TTM) 1.18 | ||
Enterprise Value to Revenue 1.55 | Enterprise Value to EBITDA 9.31 | Shares Outstanding 8057150 | Shares Floating 4335552 |
Shares Outstanding 8057150 | Shares Floating 4335552 | ||
Percent Insiders 40.39 | Percent Institutions 12.35 |
Upturn AI SWOT
CryoCell International Inc
Company Overview
History and Background
Cryo-Cell International, Inc. was founded in 1989 and is headquartered in Oldsmar, Florida. It was one of the first private cord blood banks to separate and store stem cells. The company focuses on the cryopreservation of umbilical cord blood and umbilical cord tissue for potential future medical use.
Core Business Areas
- Cord Blood Banking: Collection, processing, and cryopreservation of umbilical cord blood stem cells.
- Cord Tissue Banking: Collection, processing, and cryopreservation of umbilical cord tissue.
- Family Health Registry: Offering a family health registry to support stem cell research and potential future use.
Leadership and Structure
The leadership team typically includes a CEO, CFO, and other key executives responsible for operations, sales, and marketing. Organizational structure is hierarchical, with departments focusing on laboratory operations, customer service, sales, and research & development.
Top Products and Market Share
Key Offerings
- Competitors: Cord Blood Registry (CBR), ViaCord, Americord Registry
- Cord Blood Stem Cell Storage: The core offering involves collecting, processing, and storing stem cells from umbilical cord blood. Market share data is hard to define since there are many small players and few big ones. The cord blood banking market is competitive, with players like Cord Blood Registry (CBR) and ViaCord. Number of clients unknown.
- Competitors: Cord Blood Registry (CBR), ViaCord, Americord Registry
- Cord Tissue Storage: Storage of cells extracted from umbilical cord tissue which contain mesenchymal stem cells. Revenue is generated through subscription packages that average around $4000 for a twenty-five-year storage agreement. Number of clients unknown.
Market Dynamics
Industry Overview
The cord blood banking industry is driven by increasing awareness of the potential of stem cells in treating various diseases. The market is competitive and regulated.
Positioning
Cryo-Cell International positions itself as a leading provider of cord blood and cord tissue banking services, emphasizing quality and security. They compete based on price, reputation, and customer service.
Total Addressable Market (TAM)
The global cord blood banking market is projected to reach billions of USD. Cryo-Cell International is a mid-sized player seeking to grow within this expanding market.
Upturn SWOT Analysis
Strengths
- Established brand name
- Early mover advantage
- Focus on quality and customer service
- Wide range of storage options
Weaknesses
- High cost of services
- Market is heavily reliant on marketing to new parents, and not on real results.
- Competition from larger players
- Regulatory scrutiny
Opportunities
- Expansion into new geographic markets
- Development of new stem cell applications
- Partnerships with healthcare providers
- Increased public awareness of stem cell benefits
Threats
- Intense competition
- Changing regulations
- Economic downturns affecting affordability
- Technological advancements disrupting storage methods
Competitors and Market Share
Key Competitors
- VIAC
- LIFE
- PRIVATE CBR (Subsidiary of AMAG Pharmaceuticals)
- CORD
Competitive Landscape
Cryo-Cell faces competition from larger, well-funded players. Its advantages include its established brand and focus on customer service. Disadvantages include smaller scale and limited marketing resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth would be assessed based on revenue growth over the past few years.
Future Projections: Future growth projections would depend on analyst estimates and company guidance.
Recent Initiatives: Recent strategic initiatives would involve new product offerings, market expansion, and partnerships.
Summary
Cryo-Cell International is a key player in the cord blood banking industry with an early mover advantage. However, they face strong competition and regulatory challenges. Growth opportunities lie in market expansion and new product development. The company should focus on managing costs and adapting to industry changes to maintain its position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Financial News Outlets
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CryoCell International Inc
Exchange NYSE MKT | Headquaters Oldsmar, FL, United States | ||
IPO Launch date 1997-01-21 | Chairman & Co-CEO Mr. David I. Portnoy | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 82 | Website https://www.cryo-cell.com |
Full time employees 82 | Website https://www.cryo-cell.com | ||
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.